Transforming growth factor β and its role in heart disease.

Myocardial infarction (MI) is a major form of heart disease that leads to immediate cardiomyocyte death due to ischemia and eventually fibrosis and scar formation and further dysfunction of myocardium and heart failure. Extracellular matrix (ECM) production and tissue repair is conducted by myofibroblasts, which are formed from the normal quiescent cardiac fibroblasts following transformational changes, through the active participation of transforming growth factor β (TGFβ) and its signaling pathways. TGFβ appears to be a 'Master of all trades', with respect to cardiac fibrosis, as it can promote cardiomyocyte apoptosis and cardiac hypertrophy. TGFβ signaling involves its binding to TGFβ receptor type II (TGFβRII), which recruits TGFβ receptor type I (TGFβRI), which are also known as activin receptor-like kinase (ALK) in five different isoforms. In canonical signaling pathways, ALK5 activates Smads 2 and 3, and ALK1 activates Smads 1 and 5. These pairs of Smads form a corresponding complex and then bind to Smad 4, to translocate into the nucleus, where transcriptional reprogramming is carried out to promote myofibroblast formation and ECM production, eventually leading to cardiac fibrosis. TGFβ levels are elevated in MI, thereby aggravating the myocardial injury further. Several microRNAs are involved in the regulation of TGFβ signaling at different steps, affecting different components. Therapeutic targeting of TGFβ signaling at ALK1-5 receptor activity level has met with limited success and extensive research is needed to develop therapies based on the components of TGFβ signaling pathway, for instance cardiac dysfunction and heart failure.

Introduction

Heart diseases affect millions of individuals worldwide and the mortality due to different types of heart diseases, both congenital and acquired is steadily increasing. Myocardial infarction (MI) is a major form of heart disease that leads to immediate cardiomyocyte death due to ischemia. Even intervention with reperfusion in a timely manner, causes reperfusion injury to the myocardium, by promoting post-infarct heart remodeling, which is a known cause of heart failure (1).

A fundamental problem during heart remodeling is cardiac fibrosis, which is promoted by the formation of myofibroblasts and excessive section of extracellular matrix (ECM). There are three major types of cells in the heart, including cardiomyocytes, which are contractile, fibroblasts, which consist of 10–30% of total cells, i.e., even more than cardiomyocytes (1), in adult heart and provide structural support and vascular cells, which are important for vascularization (2). Fibroblasts are known to secrete ECM into the interstitial space, which is necessary for providing structural organization and support to myocardium (3,4) and thus play an important role in tissue replacement and repair following injury to myocardium. However, this ability of ECM production and tissue repair is bestowed upon the normal quiescent cardiac fibroblasts following transformational changes into myofibroblasts, accompanied by several changes in gene expression and phenotype of the cells. Hypertension and many other vascular and heart diseases lead to cardiac fibrosis, which compromises the mechanical function of heart and thus pose serious threat to overall health and survival (3,4). Previous findings suggested that conditions associated with elevated levels of plasma levels of certain hormones such as aldosterone, angiotensin II, endothelin-1 (ET-1) and cytokines including transforming growth factor β (TGFβ), connective tissue growth factor (CTGF/CCN2) and platelet-derived growth factor (PDGF), which actively participate in the process of transformation of quiescent fibroblasts to myofibroblasts, lead to cardiac fibrosis and eventually to heart failure (5). Normally, myofibroblasts undergo apoptotic removal following their function of tissue repair, but their persistent presence in disease and stress conditions, results in excessive ECM production and cardiac remodeling and fibrosis (6). Fibrotic response arises from a concerted action of hormones such as aldosterone, ET-1 and angiotensin II and cytokines TGFβ, with the matricellular CTGF/CCN2, which amplifies the signals coming from TGFβ (7).

In this review, we discuss the role of TGFβ and its signaling in cardiac fibrosis and remodeling and heart failure. TGFβ plays an important role in post-infarct remodeling, where tissue repair involving hypertrophic growth and fibrosis take place as a compensatory mechanism in response to the loss of cardiomyocytes by apoptosis (8).

TGFβ and cardiac fibroblast transformation

It is well established that TGFβ expression is increased in response to tissue injury in general (9) and this cytokine is involved in the tissue repair process and scar formation (10). Notably, TGFβ appears to be a ‘Master of all trades’, with respect to cardiac fibrosis (11), as it can promote cardiomyocyte apoptosis (12) and cardiac hypertrophy (13). Additionally, TGFβ is upregulated in post-infarction myocardium (14) and this correlates strongly with reduced ventricular ejection fractions (15). There are three TGFβ isoforms, TGFβ1, TGFβ2 and TGFβ3 and all these are released from their binding proteins, present as a protein complex, via the proteolytic process. Although most cells in myocardium are known to release TGFβ1, macrophages that infiltrate into myocardium after myocardial injury and cardiomyocyte apoptosis to engulf the damaged cardiomyocytes, are known to release TGFβ and angiotensin II in significant quantities (16). It has been demonstrated that TGFβ, when added to fibroblast cultures in vitro, induces the expression of genes related to ECM production and thus increases ECM deposition and concomitant suppression of matrix metalloproteinase through elevation of inhibitors of matrix metalloproteinase gene expression (7). TGFβ binds to its type I and II receptors and TGFβ/Smad signaling (see below) in fibroblasts, which sets into motion the processes involved in the transformation of fibroblasts to myofibroblasts. Once formed, myofibroblasts not only secrete ECM components, but also TGFβ, angiotensin and ET-1, which in a cyclical manner, further increase the formation of more fibroblasts and ECM deposition (16). The role of TGFβ in scar formation is evident from studies showing that the treatment of wounds with anti-TGFβ-antibodies or antisense oligonucleotides directed against TGFβ, reduce both ECM production as well as scarring (17). MI and ischemia reperfusion injury to myocardium are known to elevate the levels of reactive oxygen species (ROS) in myocardial cells and this is known to increase the expression of TGFβ, which further aggravates injury and in fact the treatment of MI patients with ROS scavenger, N-acetylcysteine, was found to reduce TGFβ levels (15). Besides the transformation of fibroblasts, TGFβ1 by partnering with tumor necrosis factor-α or IL1-β, is also shown to promote epithelial to mesenchymal transdifferentiation and endothelial to mesenchymal transdifferentiation, both of which contribute to the formation of myofibroblasts (18,19). It is estimated that nearly 35% of the fibroblasts in the fibrotic areas of heart are derived through the process of endothelial to mesenchymal transdifferentiation (20).

TGFβ receptors and signaling

TGFβ exerts its cellular effects through its binding to cell surface receptors, TGFβ receptors type I (TGFβRI) and type II (TGFβRII), which are Ser/Thr kinase receptors. Engagement of TGFβ1 to TGFβRII induces its autophosphorylation, resulting in the recruitment of TGFβRI, which is also known as activin receptor-like kinase (ALK), and its heterodimerization with TGFβRI (21). After recruitment, TGFβRI phosphorylates and activates receptor-mediated Smads (R-Smad2 and R-Smad3), the downstream players in the TGFβ signaling pathway (22). R-Smads are released from Smad anchor after phosphorylation by ALK in response to TGFβ, and then they form a complex with co-mediator Smad4 (co-Smad4). This Smad complex translocates into the nucleus (Fig. 1), where it binds to promoter regions of the genes involved in ECM production and fibrotic process and enhances their expression. TGFβ signaling gets more modular and cell specific as there are five different isoforms of TGFβRI (ALK1-5), which are expressed in different cell types and function by activating Smads 2 and 3 or Smads 1 and 5 (23). ALK1 mediates the activation of Smads 1/5 whereas ALK5 activates Smads 2/3 in endothelial cells and in many other cell types, thus adding another layer of complexity to TGFβ signaling. In addition, Smads 6 and 7 are known as inhibitory Smads that counter-regulate TGFβ signaling (Fig. 1). Thus, the outcome of TGFβ1 signaling is a balance between stimulatory R-Smad2/3 and inhibitory Smad6/7 (I-Smad6/7). In addition to Smads 6 and 7, other factors such as Ski, and SnoN also act as negative regulators of TGFβ signaling (24,25). I-Smad7, which itself is induced by TGFβ, acts as a negative feedback regulator by targeting TGFβRI for degradation through Smurf2, a Smad ubiquitination protein (26). By contrast, SnoN and Ski, which are ubiquitously expressed, negatively modulate TGF-β1 signaling at the gene transcription. Besides ALK-mediated signaling, TGFβ also mediates signaling directly via TGFβRII, by activating kinases such as TAK1, RhoA, ERK, and p38 (27) and also through the regulation of microRNAs (miRNAs), both at the transcriptional and post-transcriptional level (28).

Figure 1.

TGFβ signaling pathways that lead to myofibroblast formation. Binding of TGFβ to TGFβRII leads to its autophosphorylation and recruitment of TGFβRI (also known as ALK1-5). In normal canonical signaling, Smads 2 and 3 are activated by ALK5, followed by complex formation with Smad 4, for translocation into nucleus and activation of transcriptional program relevant for myofibroblast transformation. ALK1 activates Smads 1 and 5. Translocation of Smad complex into nucleus is inhibited by Smads 6 and 7, which prevent myofibroblast formation. In non-canonical signaling of TGFβ1, TGFβRII phosphorylates and activates RhoA, Ras and/or TAK1, which further activate ROCK, ERK and p38, respectively. TGFβ, transforming growth factor β; TGFβRII, transforming growth factor receptor type II; TGFβRI, transforming growth factor receptor type I; ALK, activin receptor-like kinase.

Importance of Smad 3 in TGFβ-mediated signaling and subsequent fibrotic response became evident in studies using Smad 3-knockout (KO) mice. Thus, it has been demonstrated that there is accelerated wound healing and low scar tissue formation, and reduced inflammation in Smad3-KO mice (29). Moreover, infarcted hearts from Smad3-KO mice display reduced cardiac fibrosis in comparison to wild-type mice (30). Isolated cardiac fibroblasts from Smad3-KO mice are unable to respond to TGFβ to produce elevated levels of collagen and other ECM components, such as pro-collagen III and tenascin-C (31,32), indicating the essential role of Smad 3 in TGFβ signaling and fibrotic processes. Non-canonical pathways of TGFβ signaling are also involved in the expression of α-smooth muscle actin (αSMA) expression and CTGF/CCN2 expression by the myofibroblasts (33,34).

TGFβ signaling and miRNAs

miRNAs are important in the modulation of TGFβ signaling and cardiac fibrosis. Thus, it has been shown earlier that miR24 prevents conversion of latent TGFβ to active form (35) and protects myocardium from post-infarction apoptosis and loss of cardiomyocytes in transgenic mice with cardiomyocyte-specific overexpression of miR24 (36). Similarly, it has been observed that miR503 is upregulated in the mouse left ventricles subjected to transverse aortic constriction and also in neonatal cardiac fibroblasts treated with angiotensin II in cell culture. miR-503 has been found to promote cardiac fibrosis involving the Apelin-13-TGFβ-CTGF-collagen production pathway (37). In another study, miR101a was shown to protect from hypoxia-induced cardiac fibrosis by targeting TGFβRI (ALK) in cardiac fibroblasts (38). Another miRNA, miR92a appears to be involved in promoting fibrosis induction by TGFβ by maintaining inhibitory Smad 7 at low levels. Thus, antagomirs against miR92a have been shown to protect hypoxia/reoxygenation induced apoptosis of cardiomyocytes (39). In a more recent study, it has been shown that miR19a-3p/19b-3p was present at low levels in the plasma of heart failure patients and that miR19a-3p/19b-3p mimics are inhibitory to epithelial mesenchymal transition and ECM production and invasion of cardiac fibroblasts. These miRs are found to antagonize autophagy of cardiac fibroblasts by targeting TGFβRII mRNA (40). In an elegant study, Tijsen et al (41) demonstrated that expression of the miR15 family was elevated in models of overloaded heart and cardiac hypertrophy and fibrosis in a protective response, as antimiRs against miR15 aggravated the fibrosis and hypertrophy in mice. miR15 was found to target TGFβRI (ALK) and other components of this signaling pathway. Thus it appears that several miRNAs are involved in the regulation of TGFβ signaling and its effects on cardiac function.

Pathological effects of TGFβ and Smad signaling

As mentioned before, several lines of experimental evidence suggest the importance of Smad signaling in TGFβ-mediated detrimental effects in cardiac dysfunction and failure (Fig. 2). Thus, it has been shown that decoy-oligonucleotides targeting Smads were found to prevent TGFβ-induced apoptosis in cardiomyocytes (12). Interruption of Smad 2 signaling by inhibiting ALK receptors using SB431542, also prevented TGFβ-induced apoptosis in cardiomyocytes (42). As detailed above, targeting Smads with miRNAs has been shown to be protective against TGFβ-mediated detrimental effects (36). Of note, it has been demonstrated that activation of alternate Smad signaling pathways is able to prevent MI-mediated cardiomyocyte death. Thus, bone morphogenetic protein-2 (BMP2), another TGF family member, which activates Smad 1/5/8 signaling via ALK1, 2 or 3 receptors, is able to alleviate post-MI cardiomyocyte death and improve heart function (43). Additionally, endothelial mesenchymal transdifferentiation, which is known to contribute to myofibroblasts, is significantly decreased in Smad 3-KO mice and also by injection of BMP7 (44). Smad 3-KO mice have been found to display reduced fibrosis following MI. Protected diastolic function and isolated cardiac fibroblasts from these KO mice do not show enhanced collagen synthesis in response to TGFβ and also markedly lowered migration and transdifferentiation potential to become myofibroblasts (30,45). Inasmuch as Smad 3-KO did not alter early immune and inflammatory responses of myocardium, Smad 3 pathway is a potential therapeutic target for reduction of the fibrotic response following MI and hypoxia/reperfusion injury. There is gene dosage effect on TGFβ signaling with regard to Smad 3 expression, as mice heterozygous for Smad3 are protected from cardiac hypertrophy induced by diabetes (46). Novel ALK inhibitors such as GW788388 have been found to curtail Smad 2 activation, myofibroblast formation, ECM deposition as well as systolic dysfunction, without changing TGFβ levels and macrophage infiltration, which is necessary for myocardial injury healing (47). However, other ALK inhibitors were found to have several unwanted side effects including increased mortality and valve lesions (48,49), thus raising concerns in targeting this target. Overexpression of inhibitory Smad 7 in vivo, inhibited angiotensin II-induced fibrosis and loss of contractility, whereas in vitro overexpression curtailed ROS-induced expression of matrix metalloproteases and collagen (50).

Figure 2.

Pathological effects of TGFβ signaling and heart failure. Hypoxia/reperfusion injury, overload and/or myocardial infarction lead to heart dysfunction through TGFβ signaling. The canonical and non-canonical signaling pathways of TGFβ trigger cardiac hypertrophy, apoptosis of cardiomyocytes and fibrosis, which all culminate in scar formation in the infarct area, cardiac remodeling and eventually heart failure. TGFβ, transforming growth factor β.

Besides the canonical pathways, non-canonical signaling through TAK1 is important in TGFβ-mediated effects on cardiac dysfunction and hypertrophic response. TAK1-mediated effects appear to involve p38 MAPK and other effectors such as TAK1 binding protein and JNK kinases (51). Extensive understanding of this complex signaling pathway is imperative in order to develop therapies targeting the components of TGFβ signaling pathway.

Conclusions

MI leads to immediate cardiomyocyte death due to ischemia and fibrosis and further dysfunction of myocardium and heart failure. Fibrosis is deposition of ECM, which is conducted by myofibroblasts, which are formed from the normal quiescent cardiac fibroblasts, through the active participation of TGFβ and its signaling pathways. TGFβ appears to be responsible for cardiac fibrosis, cardiomyocyte apoptosis and cardiac hypertrophy. TGFβ signaling involves its binding to TGFβRII receptor, which recruits TGFβRI receptors, also known as ALK in five different isoforms. Canonical signaling pathways of TGFβ involve activation of Smads, which translocate into nucleus, where transcriptional reprogramming is carried out to promote myofibroblast formation and ECM production, eventually leading to cardiac fibrosis. TGFβ levels are elevated in MI, thereby aggravating the myocardial injury further. Therapeutic targeting of TGFβ signaling at ALK1-5 receptor activity level has met with limited success and investigation is needed to develop therapies based on TGFβ signaling pathway, for cardiac dysfunction and heart failure.